Kornimate/medical-research-clean huggingface dataset:
a comparison of metallic staples versus absorbable staples after a cesarean section (c-section)

Conditions: Cesarean Section

Summary: the purpose of the study is to compare post operative pain, cost effectiveness, speed of closure and patient satisfaction of pfannenstiel incisions closed with metallic staples versus absorbable staples (insorb) after cesarean delivery.

the ideal method of closing the skin following a pfannenstiel incision has not yet been established. presently, the method of skin closure is a matter of the surgeon's personal preference. currently, there is limited evidence regarding which method is considered "superior" in terms of post operative pain, patient satisfaction, and cost effectiveness. this information would be incredibly valuable in helping guide surgeons in their choice of skin closure technique; and with the rates of cesarean deliveries rapidly rising, it is important to determine the best method of skin closure in order to optimize patient care. after a patient is consented she will be randomized into either the control group and receive the standard metallic staples or the experimental group and receive the absorbable staples for her skin closure procedure. one day after her procedure the rn will ask the patient to rate her pain using a 10cm vas pain scale. two or three days after the skin closure and before the patient is discharged a short survey about the patient's satisfaction of her scar appearance will be administered. the pi will go back and review the patient's chart to determine the amount of narcotics administered.

Eligibility criteria:
inclusion criteria: * obstetric service patients (receiving prenatal care from the faculty medical center) * women greater than 18 years old * singleton gestation * cesarean section performed by pfannenstiel skin incision exclusion criteria: * history of drug or alcohol abuse * contraindication to post operative nsaid's or narcotics * emergent cesarean deliveries * less then 18 years of age

Keywords: metallic staples absorbable staples cesarean delivery
trial of weaning of nasal continuous positive airway pressure (cpap)

Conditions: Preterm Neonates

Summary: to compare the 2 methods of weaning of nasal cpap in premature babies born at 32 weeks or less

objective: to study the weight and the post menstrual age (pma) at the time of nasal cpap (ncpap) wean utilizing the method of sudden wean as compared to gradual wean. . methods: a prospective randomized trial was conducted comparing sudden weaning with gradual weaning from ncpap in neonates with gestational age (ga) \<32 weeks. the patients were randomized to one of the two methods of weaning from ncpap and their success was compared.

Eligibility criteria:
inclusion criteria: all babies born with ga \<32 weeks admitted to the neonatal intensive care units at the maimonides infant and children's hospital, between 1st january 2008 and 31st march 2009 and required to be on ncpap for longer than 48 hours.- exclusion criteria: those with severe congenital anomalies and chromosomal defects including congenital heart disease and neurological malformations, chest wall or airway abnormalities and lung hypoplasia, were excluded from the cohort

Keywords: neonatal nasal cpap randomized controlled trial weaning
effect of manuel therapy on tonus, proprioseption and balance in multiple sclerosis

Conditions: Postural Balance; Multiple Sclerosis; Cervical Region Disorder Nos; Muscle Tonus; Proprioception

Summary: this study is investigates the effect of cervical mobilization on tonus, position sense and balance in patient with multiple sclerosis. half of participants will received classic rehabilitation program, while the other half will received servical mobilization in addition to classic rehabilitation program.

cervical region is rich in terms of muscle spindle and reseptors. when this region is touched by physiotherapists, muscle spindles is activited. thus position sense of joint and balance is developed. besides, cervical region is parasympathetic area have common relaxed effect. thus this part can be benefit to regulation of tonus.

Eligibility criteria:
inclusion criteria: * expanded disability status scale (edss) score was between 2-5, * according to the modified ashworth scale, spasticity is between 1 and 3, * edss cerebellar system sub-scale, functional system score ˃1, * medical condition is stable and no medication changes were made in the last month, * vertebro-basillar test negative, * not have any other neurological disorder and orthopedic problem to prevent participation in this study * a score of at least 24 from the mini mental test, exclusion criteria: * presence of psychiatric or severe cognitive dysfunction, * pregnancy, * having a neurological disease other than ms, * having had an attack in the last 3 months, * botulinum toxin application within the last 6 months, * participating in physiotherapy program in the last 6 months
combination of ertugliflozin and sitagliptin efficacy, safety & tolerability (cease diabetes) study

Conditions: Efficacy; Safety; Tolerability

Summary: open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of ertugliflozin and sitagliptin con-initiation in patients with type ii diabetes mellitus in the pakistani population. the study duration will be 12 months.


Eligibility criteria:
inclusion criteria: * type 2 diabetic males \& females between 18-65 years. * hba1c: 7.0% - 10.0% * patient uncontrolled on oral anti-diabetics and lifestyle modifications for at least 3 months. * egfr \>60 ml/min/1.73m2. * patient who will give informed consent * patient who are sglt2i naïve exclusion criteria: * history of severe hypoglycemia for the last three months (\<70mg/dl) * pregnant or lactating females * history of renal and/or hepatic dysfunctions, where rft and urine r/e is abnormal * history of recurrent urinary tract infection (uti) and/or past 3 months' history of uti and its treatment * patients who have been admitted to the hospital in the past 3 months for diabetic ketoacidosis (dka) and hyperosmolar hyperglycemic state. * history of acute coronary syndrome or myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack. * history of active liver disease, including chronic active hepatitis b or c, primary biliary cirrhosis, or symptomatic gallbladder disease * patient with diabetic foot ulcers

Keywords: efficacy, safety, tolerability, ertugliflozin, sitgliptin
a study of recombinant anti-il-1β humanized monoclonal antibody injection in chinese participants with acute gout

Conditions: Acute Gout

Summary: the purpose of this study is to determine the efficacy and safety of recombinant anti-il-1β humanized monoclonal antibody injection in chinese participants with acute gout.

study ssgj-613-ag-iii-01 is a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study examining the effect of recombinant anti-il-1β humanized monoclonal antibody injection versus compound betamethasone injection in chinese adult patients with frequent flares of acute gouty arthritis who are contraindicated, intolerant, or lack efficacy to non-steroidal anti-inflammatory drugs (nsaids) and/or colchicine. the entire treatment period is 48 weeks, consisting of a double-blind treatment period of 24 weeks and an open treatment period of 24 weeks.

Eligibility criteria:
inclusion criteria: * must be 18 years to 75 years, both male and female. * bmi ≤35 kg/m2. * meeting the american college of rheumatology (acr) 2015 criteria for the classification of acute arthritis of primary gout. * history of ≥ 3 gout flares within the 12 months prior to study randomization. * onset of current acute gout flare within 4 days prior to study screening. * screening pain intensity of the target joint ≥ 50 mm on the 0-100 mm vas. * contraindicated, intolerant or lack efficacy to nsaids and/or colchicine. * accept uric acid lowering treatment according to the requirements of the protocol. exclusion criteria: * gout caused by radiotherapy/chemotherapy, lead, organ transplantation, tumors, etc. * evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis. * presence of severe renal function impairment. * intolerance of subcutaneous and intramuscular injection. * known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment. * history of malignant tumor within 5 years before screening. * live vaccinations within 8 weeks prior to the start of the study. * use of forbidden therapy.
pulmonary embolism short-term clinical outcomes registry

Conditions: Pulmonary Embolism

Summary: the overall goal of this clinical research study is to prospectively assess primary outcomes related to pulmonary embolism (pe) that occur immediately (within 5 days) and within 30 days. the secondary goal is to compare validated prediction models and a modified european society of cardiology (esc) approach that is primarily right ventricle dysfunction (rvd) driven with clinical risk assessment being secondary, and with primary outcomes of clinical deterioration within 5 days.

the investigators wish to develop the pulmonary embolism short-term clinical outcomes registry (pe-scor). the investigators also wish to determine the incidence of death and circulatory and respiratory deterioration, and administration of reperfusion therapy within 5 days in pe patients. the study will also evaluate the sensitivity, specificity and positive and negative predictive values of each rvd assessment option. the investigators will also derive a prediction model for pe patients for the primary outcome within five days. finally, investigators will determine the functional outcomes of pe patients 30 days after pe.

Eligibility criteria:
inclusion criteria: * patients 18 years or older with image confirmed acute pulmonary embolism diagnosed within 12 hours of ed presentation will be eligible for enrollment. exclusion criteria: * patients who refuse consent for 30-day clinical contact and follow-up.
sleep disorders and gastroesophageal reflux disease (gerd)

Conditions: Insomnia; GERD

Summary: this study will investigate gastroesophageal reflux disease (gerd)as a cause of sleep disturbance. patients with gerd may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation) and belching. even very small, unnoticeable amounts of rising stomach acid may cause patients to wake up during the night. this study will also investigate the effect of rabeprazole, (brand name aciphex) on patients with known insomnia. rabeprazole is an fda approved medication already marketed for the treatment of gerd.

participants with known insomnia will undergo an overnight ph and sleep study. those found to be eligible after the first sleep study (those with significantly poor sleep quality and no significant sleep apnea) will be started on 2 weeks 20 mgs, twice-a-day, rabeprazole. upon completion of the 2 week course of rabeprazole, subjects will repeat the overnight ph and sleep studies. upon completion of these studies, participation is complete.

Eligibility criteria:
inclusion criteria: 1. english-speaking male or female subjects, 18-75 years of age. (women must be two (2) years post-menopausal or surgically sterile. women of childbearing potential or \<1 year post-menopausal must be practicing an approved method of contraception and have a negative urine pregnancy test at screening.), 2. a six-month duration of insomnia, 3. sleep difficulty at least 3 nights per week, and a sleep study demonstrating \> 10 arousals/hour for those aged \ 15 for those who are 45 or older. exclusion criteria: 1. bmi \> 30 or history of snoring (in order to decrease the prevalence of sleep apnea in the sample), 2. use of any proton pump inhibitor or h2 receptor antagonist within one week of undergoing initial sleep study, 3. previous acid-suppressing medication for sleep disturbances, 4. previous surgical antireflux procedure, 5. current medical therapy that includes digoxin or ketoconazole, 6. previous aerodigestive malignancy, 7. a previously diagnosed psychological or medical cause of insomnia (other than suspected gerd), and 8. inability or unwillingness to provide consent for the procedures.

Keywords: insomnia gastroesophageal reflux disease (gerd) sleep disturbance
a study to assess the safety and efficacy of an investigational drug in patients with osteoarthritis (0663-071)(completed)

Conditions: Osteoarthritis

Summary: this study was conducted to assess the safety and tolerability of the drug and to evaluate its efficacy in the treatment of osteoarthritis of the hip or knee in men and women.


Eligibility criteria:
inclusion criteria: * patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee * either prior nsaid or acetaminophen users within the the ara functional class i,ii or iii * patients required to demonstrate a "flare" of the signs and symptoms of oa following withdrawal of nsaid treatment * prior acetaminophen users also required to demonstrate greater than a defined minimum level of signs and symptoms of oa. exclusion criteria: * no history of concurrent arthritic disease * uncontrolled hypertension or an active cardiac condition * no history of hepatitis, neoplastic disease, stroke or transient ischemic attack within a specified duration.

Keywords: arcoxia
modeling amyotrophic lateral sclerosis with fibroblasts

Conditions: Amyotrophic Lateral Sclerosis

Summary: amyotrophic lateral sclerosis (als) is the most common motor neuron disease in adults. this longitudinal study involves three cohorts of participants: patients with sporadic or hereditary als, asymptomatic individuals carrying pathogenic mutations responsible for als, and control subjects. in this study, a skin biopsy and blood sampling will be performed at the initial visit (m0), then at m12 (+/- 2 months) for patients, and at m36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. the aim of this research is to model als pathology using fibroblasts derived from the patients' skin biopsies.

amyotrophic lateral sclerosis (als) is the most common motor neuron disease in adults. this longitudinal study involves three cohorts of participants: patients with sporadic or hereditary als, asymptomatic individuals carrying pathogenic mutations responsible for als, and control subjects. in this study, a skin biopsy and blood sampling will be performed at the initial visit (m0), then at m12 (+/- 2 months) for patients, and at m36 (+/- 12 months) for asymptomatic carriers of pathogenic mutations. the aim of this research is to model als pathology using fibroblasts derived from the patients' skin biopsies.

Eligibility criteria:
inclusion criteria common to all 3 populations: * adults, both sexes * with written consent to participate in the study * affiliated to a social security scheme als patients : * patients with als according to the revised el escorial criteria : * with a hereditary form of als, defined by the presence of a family history of als or by the demonstration of a pathogenic mutation in the patient or * with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or * with a sporadic form of als asymptomatic mutation carriers : - asymptomatic individuals who carry a mutation causing als but have not developed symptoms. healthy subjects: * control individuals, taking into account male/female and close age matching exclusion criteria: * with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a contraindication to skin biopsy * have a platelet count of less than 75,000/mm3 in a laboratory test less than 3 months old, * with a proven allergy to lidocaine or prilocaine, * pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice. * patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study. * participation in a clinical trial (involving a drug) or other interventional research if this interferes with fibrals research.

Keywords: amyotrophic lateral sclerosis genetic fibroblasts
study on neoadjuvant chemotherapy for advanced gastric cancer

Conditions: Advanced Gastric Carcinoma

Summary: gastric cancer is the second cause of cancer related death and china has the most gastric cancer patients in the world. although systemic strategies, including adjuvant chemotherapy, postoperative chemoradiotherapy, perioperative chemotherapy, have evolved and showed benefits these years, the prognosis of advanced gastric cancer is still not satisfactory. optimal regimens and optimal method administration is still being found. neoadjuvant chemotherapy has many advantages, including downstaging the tumor, increasing r0 rate, early eradicating of micrometastasis. in previous trials, combination of paclitaxel and s-1 has showed safety and tolerance in recurrent or metastatic gastric cancer. using liposome as a carrier, paclitaxel has a better histocompatibility and cellular affinity, resulting a improved stability and reduced toxicity. in this phase ii trial, we are going to study the safety and feasibility of paclitaxel liposome plus s-1 as neoadjuvant chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically confirmed gastric cancer * disease at clinical stage of resectable or potentially resectable(t3-4, n0-3, m0) by ct and endoscopic ultrasonography (eus) * karnofsky performance status(kps） ≥ 70 * no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy * life expectancy more than 3 months * adequate organ function as defined below:white blood cell count （wbc） ≥ 3.0\*10\^9/l, absolute neutrophil count （anc） ≥ 1.5\*10\^9/l, hemoglobin ≥ 100 g/l, platelets ≥ 100\*10\^9/l, total bilirubin （tbil） ≤ 1.5mg/dl, aspartate aminotransferase（ast） and alanine aminotransferase(alt) ≤ 2.5×uln, alkaline pposphatase( alp) ≤ 2.5×uln, renal serum creatinine \< 1.5mg/dl * adequate lung and heart function exclusion criteria: * ≥ grade 2 neuropathy * history of malignancy * with uncontrolled central nervous system metastasis * concurrent disease or condition that would interfere with the subject's safety (including current active hepatic, biliary, renal, respiratory disease, acute infection, severe malnutrition, uncontrolled diabetes hypertension et al) * severely inadequate intake of water or diet

Keywords: advanced gastric cancer neoadjuvant chemotherapy safety feasibility
pas balance training for parkinson disease (pd)

Conditions: PD - Parkinson's Disease

Summary: gait initiation (gi) difficulty is a common problem in individuals with parkinson's disease (pd), often linked to impaired anticipatory postural adjustments (apa). currently, there are no targeted rehabilitation programs designed specifically for gi-related apa in pd patients. research has shown that while motor learning deficits are common in pd, explicit learning is better preserved than implicit learning. therefore, a gi-related apa training system using an explicit learning model could be particularly effective for this population. during motor learning, long-term potentiation (ltp) increases the excitability of the primary motor cortex. paired associative stimulation (pas) has been demonstrated to induce ltp-like changes in the motor cortex, making it a potential priming method to enhance motor learning. however, the priming effect of pas targeted at leg muscles and the motor cortex on motor learning related to gi-apa has not been previously studied. the objectives of this study are: 1. to investigate the effects of explicit and implicit training on gi-related apa. 2. to evaluate the priming effect of pas on gi-related apa training and the associated plasticity changes in the motor cortex.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of parkinson disease. exclusion criteria: * musculoskeletal injuries on legs * osteoporosis. * any peripheral or central nervous system injury or disease patients.

Keywords: gait initiation paired associative stimulation (pas) balance training motor learning anticipatory postural adjustment (apa)
evaluating new mexico's recidivism reduction program

Conditions: Behavior

Summary: a a multi-site trial to measure the efficacy of the recidivism reduction program, a prison based, twenty-one module reentry program operated by the new mexico department of corrections.

the new mexico department of corrections recidivism reduction program (rrp) is designed to provide offenders with knowledge and skills that are transferable to the community setting and to address issues that offenders will invariably face upon release to the community. transitional coping skills, offender expectations upon release, family issues, and dealing with authority figures are a few of the challenges facing offenders upon reintegration. the recidivism reduction program is aimed at preparing offenders for the potential obstacles that they may encounter upon release to the community and providing them skills to overcome the challenges that they will face. the rrp curriculum focuses on belief systems, self-esteem, and rational thinking. the rrp is a twenty-one module clinician-led program (approximately 100 hours) delivered in a group setting within months of release. outcomes focus on measures of transition readiness, successful transition into the community, and recidivism.

Eligibility criteria:
inclusion criteria: * inmates who have six months prior to release * inmates housed at one of the four experimental prisons * inmates willing to participate in the recidivism reduction program exclusion criteria: - housed in security level 4 or 5

Keywords: behavior drug users inmates